Attestation committee
Accreditation committee
Expert committee
Dispositions, instructions
Normative acts
Nomenclature
Institutions
Scientific councils
Seminars
Theses
Scientific advisers
Scientists
Doctoral students
Postdoctoral students
CNAA logo

 română | русский | english

CNAA / Theses / 2010 / July /

Biotechnology of obtaining the medicine for treatment of benign prostatic hyperplasia


Author: Ciuhrii Veaceslav
Degree:doctor of biology
Speciality: 03.00.23 - Biotechnology
Year:2010
Scientific adviser: Valeriu Rudic
doctor habilitat, professor, Institute of Microbiology and Biotechnology of the ASM
Institution: Institute of Microbiology and Biotechnology of the ASM
Scientific council: DH 09-03.00.23
Institute of Microbiology and Biotechnology of the ASM

Status

The thesis was presented on the 20 July, 2010
Approved by NCAA on the 6 October, 2010

Abstract

Adobe PDF document0.89 Mb / in romanian

Keywords

benign prostatic hyperplasia, Lymantria dispar, water-alcohol extract, specific antioxidant activity, clinical efficiency

Summary

Ciuhrii Veaceslav, „Biotechnology of obtaining the medicine for treatment of benign prostatic hyperplasia”. Dissertation of Doctor of Biological Sciences, Chişinău, 2010. Dissertation contains Introduction, 4 Chapters, Main Conclusions and Practical Recommendations, List of literature consisting 182 titles, 11 annexes, 102 pages of main text, 12 tables and 25 pictures. The results of the work were published in 9 scientific papers.

Goal of the work: development of biotechnology for the obtaining of medicine based on insects, for the treatment of benign prostatic hyperplasia.

Tasks: selection of the insect species as a source of biologically active substances with antiradical and antioxidant properties; development of optimal parameters for the efficient extraction of antioxidant substances from insect biomass, development of complex technological schema for obtaining of medicine for the treatment of benign prostatic hyperplasia, biomedical and clinical studies of the efficiency of the developed medicine in the treatment of benign prostatic hyperplasia.

Scientific novelty. First time the new approach for the development of medicine for the treatment of benign prostatic hyperplasia is proposed, namely the evaluation of practicability of biologically active substances considering their specific antioxidant activity.

Theoretical importance: It is proved that the active substance, obtained from Lymantria dispar larvae, has high stability and specific antioxidant activity, inhibiting the oxidation of low density lipoproteins and reducing the NO radical.

Applied importance. Main result of the work is the new medicine ADENOPROSIN 250 mg suppositories, which is developed, registered, introduced into production, and successfully used in medical practice.

Application of scientific results. Active substance ADENOPROSIN is produced by SC NEW TONE TRADING SRL, medicine is produced by FARMAPRIM SRL. Medicine is available in 5 countries.